The Melanoma Letter 2019, Vol. 37, No. 1

The Melanoma Letter

Download PDF

In this issue of The Melanoma Letter, Jeffrey Zhao and Drs. Galvez and Sosman describe the evolution of the exciting developments in melanoma adjuvant therapy and detail the benefits and limitations of the new and impending treatments. In a second article, they address an even newer development, neoadjuvant therapy, treating stage IIIA–C patients before they have been operated on, to reduce tumor size and prime the immune system in the presence of tumor to improve survival.